Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340436 | 0.75 | LIMK1 (0.38) | — | |
| SCHEMBL18673118 | 0.73 | CCR1 (0.43) | SLC40A1HSP90AA1CCR1CCR5CCR8 | |
| SCHEMBL15340420 | 0.70 | NR4A2 (0.32) | NR4A2 | |
| SCHEMBL18673064 | 0.69 | — | — | |
| SCHEMBL1071707 | 0.67 | NR4A2 (0.59) | NCF1NR4A2SLC40A1HSP90AA1HSP90AB1 | |
| SCHEMBL15340427 | 0.67 | NR4A2 (0.39) | NCF1NR4A2SLC40A1HSP90AA1HSP90AB1 | |
| SCHEMBL23188728 | 0.66 | PDPK1 (0.46) | — | |
| SCHEMBL4390960 | 0.65 | NR4A2 (0.57) | NCF1NR4A2SLC40A1HSP90AA1HSP90AB1 | |
| SCHEMBL16381310 | 0.63 | NR4A2 (0.48) | NCF1NR4A2HSP90AA1HSP90AB1IDO1 | |
| SCHEMBL14682709 | 0.63 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1IDO1PSMB5CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-09-28 | — | — | US | disclosed |
| US-9487544-B2 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160016980-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9090642-B2 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016980-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | NCF1 2420/4885NR4A2 2778/4885SLC40A1 1073/4885 |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | NCF1 2420/4885NR4A2 2778/4885SLC40A1 1073/4885 |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PNP, PAICS, NUDT1 | NCF1 1840/4885NR4A2 2643/4885SLC40A1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.